NO20073103L - Konjugater av insulinlignende vekstfaktor-1 og poly(etylenglykol) - Google Patents
Konjugater av insulinlignende vekstfaktor-1 og poly(etylenglykol)Info
- Publication number
- NO20073103L NO20073103L NO20073103A NO20073103A NO20073103L NO 20073103 L NO20073103 L NO 20073103L NO 20073103 A NO20073103 A NO 20073103A NO 20073103 A NO20073103 A NO 20073103A NO 20073103 L NO20073103 L NO 20073103L
- Authority
- NO
- Norway
- Prior art keywords
- amino acid
- poly
- ethylene glycol
- insulin
- growth factor
- Prior art date
Links
- 229920001223 polyethylene glycol Polymers 0.000 title abstract 3
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title abstract 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 title abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 4
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 3
- 239000004472 Lysine Substances 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04030415A EP1674113A1 (fr) | 2004-12-22 | 2004-12-22 | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
| PCT/EP2005/013756 WO2006066891A2 (fr) | 2004-12-22 | 2005-12-21 | Conjugues du facteur de croissance 1 analogue a l'insuline et du poly(ethylene glycol) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073103L true NO20073103L (no) | 2007-09-19 |
Family
ID=34927913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073103A NO20073103L (no) | 2004-12-22 | 2007-06-18 | Konjugater av insulinlignende vekstfaktor-1 og poly(etylenglykol) |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US20060154865A1 (fr) |
| EP (2) | EP1674113A1 (fr) |
| JP (1) | JP4954896B2 (fr) |
| KR (3) | KR20090010138A (fr) |
| CN (1) | CN101123991B (fr) |
| AR (1) | AR052842A1 (fr) |
| AU (1) | AU2005318387B2 (fr) |
| BR (1) | BRPI0515857A (fr) |
| CA (1) | CA2592006C (fr) |
| CR (1) | CR9177A (fr) |
| EA (1) | EA011284B1 (fr) |
| IL (1) | IL183966A (fr) |
| MA (1) | MA29107B1 (fr) |
| MX (1) | MX2007007479A (fr) |
| NO (1) | NO20073103L (fr) |
| NZ (1) | NZ555840A (fr) |
| TN (1) | TNSN07237A1 (fr) |
| TW (3) | TW200940085A (fr) |
| UA (1) | UA93666C2 (fr) |
| WO (1) | WO2006066891A2 (fr) |
| ZA (1) | ZA200705146B (fr) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1674113A1 (fr) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
| AU2007255419A1 (en) | 2006-06-09 | 2007-12-13 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| CL2007002502A1 (es) * | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| BRPI0715754A2 (pt) | 2006-08-31 | 2013-07-09 | Hoffmann La Roche | mÉtodo para a produÇço de fator do crescimento similar Á insulina i |
| EP2274016B1 (fr) * | 2008-04-03 | 2012-07-25 | F. Hoffmann-La Roche AG | Variantes de l'igf-i pegylées pour utilisation dans le traitement des troubles neuromusculaires |
| JP2012513477A (ja) * | 2008-12-23 | 2012-06-14 | ソーク インスティチュート フォー バイオロジカル スタディーズ | 神経変性疾患の治療方法 |
| EP2456788B1 (fr) | 2009-07-22 | 2015-12-16 | Ipsen Pharma S.A.S. | Analogues au facteur-1 de croissance insulinomimétique (igf-1) présentant une substitution d'acide aminé en position 59 |
| WO2011041376A1 (fr) * | 2009-09-30 | 2011-04-07 | Prolong Pharmaceuticals | Facteur modifié de stimulation des colonies de granulocytes (g-csf) |
| US20110152188A1 (en) | 2009-12-23 | 2011-06-23 | Hanns-Christian Mahler | Pharmaceutical compositions of igf/i proteins |
| US9587006B2 (en) * | 2010-02-11 | 2017-03-07 | Hoffmann-La Roche Inc. | IGF-I poly (ethylene glycol) conjugates |
| CN101831067A (zh) * | 2010-05-31 | 2010-09-15 | 王二新 | 聚乙二醇脂类缀合物及其在制备药物中的应用 |
| EP2864353B1 (fr) * | 2012-06-25 | 2019-03-27 | The Brigham and Women's Hospital, Inc. | Thérapie sélective des cartilages |
| NZ708091A (en) | 2012-12-18 | 2018-03-23 | Novartis Ag | Stabilized insulin-like growth factor polypeptides |
| JP2016535080A (ja) | 2013-10-02 | 2016-11-10 | ノバルティス アーゲー | 療法における使用のためのインスリン様成長因子模倣物 |
| UY35874A (es) | 2013-12-12 | 2015-07-31 | Novartis Ag | Un proceso para la preparación de una composición de proteínas pegiladas |
| EP3702470A3 (fr) * | 2015-09-09 | 2020-10-07 | The Trustees of Columbia University in the City of New York | Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer |
| KR200481741Y1 (ko) | 2016-02-22 | 2016-11-04 | 강진범 | 차량의 방향지시등에 연동하여 특수 인식 영역에 led 반사광을 형성하기 위한 노면 광조사 장치 |
| JP7118508B2 (ja) | 2016-02-23 | 2022-08-16 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト | 神経損傷を治療するペプチドベースの方法 |
| RU2711111C1 (ru) * | 2018-09-05 | 2020-01-15 | Илья Владимирович Духовлинов | Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения |
| EP3911668A1 (fr) | 2019-01-18 | 2021-11-24 | The Regents of the University of Colorado, a body corporate | Peptides antimicrobiens alpha-hélicoïdaux amphipathiques pour le traitement d'infections par des agents pathogènes à gram-négatif |
| US20220299524A1 (en) * | 2021-03-19 | 2022-09-22 | Quest Diagnostics Investments Llc | Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0561137B1 (fr) | 1983-04-25 | 2002-07-03 | Chiron Corporation | Synthèse à l'aide d'ADN hybride de facteurs de croissance mûrs du type insuline |
| IL71991A (en) | 1983-06-06 | 1994-05-30 | Genentech Inc | Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5164370A (en) * | 1987-12-24 | 1992-11-17 | Gropep Pty. Ltd. | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) |
| DE69026306T2 (de) | 1989-05-27 | 1996-10-17 | Seikagaku Kogyo Co Ltd | Verfahren für die Herstellung von Polyethylenglykolderivate und modifizierte Proteine. |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| US5681814A (en) | 1990-06-07 | 1997-10-28 | Genentech, Inc. | Formulated IGF-I Composition |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5861373A (en) * | 1991-08-01 | 1999-01-19 | Genentech, Inc | IGF-1 to improve the neural condition |
| ES2101865T3 (es) | 1991-08-01 | 1997-07-16 | Genentech Inc | Igf-1 para mejorar el estado neural. |
| AU6048294A (en) * | 1992-11-25 | 1994-06-22 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| EP0756494A1 (fr) * | 1994-05-24 | 1997-02-05 | Amgen Boulder Inc. | Facteurs de croissance proches de l'insuline modifies |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| WO1998035026A1 (fr) | 1997-02-06 | 1998-08-13 | Novo Nordisk A/S | Conjugats polypeptide-polymere a groupes de fixation ajoutes et/ou retires |
| US7067485B2 (en) | 1997-11-07 | 2006-06-27 | Chiron Corporation | IGF-I composition and its use |
| US6767892B1 (en) | 1997-11-07 | 2004-07-27 | Chrion Corporation | Compositions providing for increased IGF-I solubility |
| WO1999055362A1 (fr) | 1998-04-29 | 1999-11-04 | Genentech, Inc. | Formulations de igf-i sechees par pulverisation |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
| EP1141015B1 (fr) | 1999-01-06 | 2009-07-15 | Genentech, Inc. | Variants mutants du facteur de croissance i semblable a l'insuline (igf) |
| DK1141014T3 (da) * | 1999-01-06 | 2005-04-11 | Genentech Inc | Insulinlignende vækstfaktor (IGF) i mutantvariant |
| ES2208305T3 (es) | 1999-04-08 | 2004-06-16 | Genentech, Inc. | Composicion basada en polipeptidos de carga opuesta.. |
| US7431921B2 (en) | 2000-04-14 | 2008-10-07 | Maxygen Aps | Interferon beta-like molecules |
| HUP0302674A2 (hu) * | 1999-08-27 | 2003-11-28 | Maxigen Aps. | Új, béta-interferon-szerű molekulák |
| US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
| WO2001091798A2 (fr) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
| WO2002032449A2 (fr) | 2000-10-13 | 2002-04-25 | Chiron Corporation | Procede de traitement d'accidents ischemiques affectant le systeme nerveux central |
| BR0317752A (pt) * | 2002-12-26 | 2005-11-22 | Mountain View Pharmaceuticals | Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada |
| EP1674113A1 (fr) | 2004-12-22 | 2006-06-28 | F. Hoffmann-La Roche Ag | Conjugués de l'IGF-1 et du poly(éthylène glycol) |
| CL2007002502A1 (es) | 2006-08-31 | 2008-05-30 | Hoffmann La Roche | Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer. |
| EP2274016B1 (fr) | 2008-04-03 | 2012-07-25 | F. Hoffmann-La Roche AG | Variantes de l'igf-i pegylées pour utilisation dans le traitement des troubles neuromusculaires |
-
2004
- 2004-12-22 EP EP04030415A patent/EP1674113A1/fr not_active Withdrawn
-
2005
- 2005-12-20 US US11/313,101 patent/US20060154865A1/en not_active Abandoned
- 2005-12-21 WO PCT/EP2005/013756 patent/WO2006066891A2/fr active Application Filing
- 2005-12-21 TW TW098120879A patent/TW200940085A/zh unknown
- 2005-12-21 CN CN2005800485069A patent/CN101123991B/zh not_active Expired - Fee Related
- 2005-12-21 NZ NZ555840A patent/NZ555840A/en not_active IP Right Cessation
- 2005-12-21 UA UAA200708134A patent/UA93666C2/ru unknown
- 2005-12-21 KR KR1020097000308A patent/KR20090010138A/ko not_active Application Discontinuation
- 2005-12-21 TW TW097145363A patent/TW200914041A/zh unknown
- 2005-12-21 AU AU2005318387A patent/AU2005318387B2/en not_active Ceased
- 2005-12-21 EA EA200701234A patent/EA011284B1/ru not_active IP Right Cessation
- 2005-12-21 CA CA2592006A patent/CA2592006C/fr not_active Expired - Fee Related
- 2005-12-21 BR BRPI0515857-5A patent/BRPI0515857A/pt not_active Application Discontinuation
- 2005-12-21 EP EP05849990.6A patent/EP1830889B1/fr active Active
- 2005-12-21 JP JP2007547330A patent/JP4954896B2/ja not_active Expired - Fee Related
- 2005-12-21 KR KR1020097014300A patent/KR101106860B1/ko not_active IP Right Cessation
- 2005-12-21 TW TW094145672A patent/TW200635604A/zh unknown
- 2005-12-21 KR KR1020077016867A patent/KR100915278B1/ko not_active IP Right Cessation
- 2005-12-21 MX MX2007007479A patent/MX2007007479A/es active IP Right Grant
- 2005-12-22 AR ARP050105473A patent/AR052842A1/es not_active Application Discontinuation
-
2007
- 2007-06-12 CR CR9177A patent/CR9177A/es not_active Application Discontinuation
- 2007-06-14 IL IL183966A patent/IL183966A/en not_active IP Right Cessation
- 2007-06-18 NO NO20073103A patent/NO20073103L/no not_active Application Discontinuation
- 2007-06-21 MA MA30023A patent/MA29107B1/fr unknown
- 2007-06-21 TN TNP2007000237A patent/TNSN07237A1/fr unknown
- 2007-06-21 ZA ZA200705146A patent/ZA200705146B/en unknown
-
2010
- 2010-06-02 US US12/791,904 patent/US20110009317A1/en not_active Abandoned
-
2012
- 2012-07-18 US US13/551,648 patent/US20120322732A1/en not_active Abandoned
-
2013
- 2013-03-18 US US13/845,179 patent/US20130217623A1/en not_active Abandoned
-
2014
- 2014-09-10 US US14/482,703 patent/US9724425B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073103L (no) | Konjugater av insulinlignende vekstfaktor-1 og poly(etylenglykol) | |
| AR107020A2 (es) | Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9) | |
| Abdel-Hamid et al. | Camel milk whey hydrolysate inhibits growth and biofilm formation of Pseudomonas aeruginosa PAO1 and methicillin-resistant Staphylococcus aureus | |
| DK1859041T3 (da) | Aprotininpolypeptider til transport af en forbindelse over blod-hjerne-barrieren | |
| WO2007056362A3 (fr) | Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees | |
| WO2006056885A3 (fr) | Nouveaux peptides igf-i | |
| WO2006060182A3 (fr) | Peptides hk hautement ramifies utilises en tant que porteurs efficaces de petits arn interferents | |
| BR0313429A (pt) | peptìdeos como excipientes solubilizantes para proteìnas do fator de crescimento beta de transformação | |
| WO2010011947A3 (fr) | Analogues du peptide ss-amyloïde, oligomères de celui-ci, procédés de préparation et compositions comprenant lesdits analogues ou oligomères, et leurs utilisations | |
| DE602005023315D1 (de) | Antimikrobielle peptide mit einem arginin- und /oder lysin-haltigen motiv | |
| DE602006004160D1 (de) | Niedertemperatur-Trocknungsverfahren zur Herstellung von arzneimittelhaltigen Polymerzusammensetzungen | |
| WO2006110490A3 (fr) | Agents et procedes d'inhibition d'oxysterols osteogeniques du stress oxydatif sur la differenciation cellulaire osteogenique | |
| EA200970324A1 (ru) | Композиция удлинителя цепи на основе диамина | |
| WO2009024346A3 (fr) | Utilisation de substances pour le traitement de perte de vue chez des êtres humains atteints d'un glaucome et d'autres maladies des yeux dégénératives | |
| UY31941A (es) | Un metodo para mejorar la solidez a la lluvia de glifosato | |
| AR245504A1 (es) | Molecula de dna que codifica la proteina mas abundante en el sobrenadante del cultivo de lactococous spec. | |
| WO2007029262A3 (fr) | Compositions et methodes d'utilisation de ces dernieres en vue de detecter des virus | |
| DE502005010722D1 (de) | Farbverändernde mittel mit moringa extrakt | |
| AR064252A1 (es) | Plantas que presentan caracteristicas acrecentadas relacionadas con el rendimiento y un metodo para producir las mismas | |
| AR044209A1 (es) | Composiciones farmaceuticas que comprenden epinastina para el tratamiento de enfermedades de la piel | |
| CY1110644T1 (el) | 5,6,7-τριυδροξυεπτανοϊκο οξυ και τα αναλογα για την θεραπεια οφθαλμικων ασθενειων που σχετιζονται με υπερεκφυτικες και αγγειογενεις αντιδρασεις | |
| EA200701837A1 (ru) | Гербицидные композиции на основе 3-фенилурацилов и 3-сульфонилизоксазолинов | |
| WO2011050384A9 (fr) | Composition pharmaceutique pour le traitement et la prévention d'une infection à rhinovirus | |
| WO2019148195A3 (fr) | Inhibiteurs peptidyliques cycliques du domaine de liaison cal-pdz | |
| WO2006122541A3 (fr) | Composition d'action pharmaceutique destinee au traitement de diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |